|1.||Ono, Yuri: 3 articles (09/2014 - 03/2013)|
|2.||Kaku, Kohei: 3 articles (06/2014 - 07/2013)|
|3.||Ojima, Kazuma: 3 articles (02/2006 - 01/2002)|
|4.||Kojima, Masami: 3 articles (02/2006 - 01/2002)|
|5.||Nomoto, Hiroshi: 2 articles (09/2014 - 02/2014)|
|6.||Nakamura, Akinobu: 2 articles (09/2014 - 02/2014)|
|7.||Cho, Kyu Yong: 2 articles (02/2014 - 03/2013)|
|8.||Katsuno, Tomoyuki: 2 articles (01/2013 - 06/2011)|
|9.||Hamaguchi, Tomoya: 2 articles (01/2013 - 06/2011)|
|10.||Namba, Mitsuyoshi: 2 articles (01/2013 - 06/2011)|
|1.||Type 2 Diabetes Mellitus (MODY)
11/01/2009 - "This study investigated the effects of mitiglinide in 16 patients with type 2 diabetes mellitus treated with 30 mg/day mitiglinide, divided into three doses given just before each meal, for approximately 12 months. "
11/01/2009 - "In this study, a urinary metabonomics method based on ultra-performance liquid chromatography-tandem mass spectrometry was developed to study the effect mechanism of mitiglinide on type 2 diabetes mellitus. "
06/01/2014 - "In patients with type 2 diabetes mellitus (T2DM) receiving a stable monotherapy regimen with a DPP-4 inhibitor or biguanide added to dietary therapy, an additional 10 mg mitiglinide was administered for 52 weeks. "
10/01/2010 - "Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus."
11/01/2009 - "Pleiotropic effects of mitiglinide in type 2 diabetes mellitus."
10/01/2010 - "Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies."
01/01/2012 - "Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide."
10/01/2010 - "Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. "
01/01/2012 - "These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. "
01/01/2015 - "Mitiglinide, a short-acting insulinotropic sulfonylurea receptor ligand, is effective for postprandial hyperglycemia. "
|3.||Hypoglycemia (Reactive Hypoglycemia)
10/01/2010 - "Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia. "
01/01/2010 - "Mitiglinide can be safely used for diabetic patients on HD, if careful attention is paid to hypoglycemia."
10/01/2004 - "The incidence of adverse events related to mitiglinide were nearly equivalent to placebo; in particular there was no difference with the frequency of hypoglycemia. "
10/01/2004 - "The results from these studies indicated that mitiglinide could be expected to possess good therapeutic features of being effective in reducing postprandial glucose excursions in the early stage of Type 2 diabetes and less incidence of events suggestive of hypoglycemia."
06/01/2014 - "Combination therapy with mitiglinide and DPP-4 inhibitors or biguanides improved glycemic control over the long term without increasing risks to safety due to events such as hypoglycemia, and this is a clinically promising therapeutic strategy in T2DM."
06/05/2011 - " In the present study, we compared the efficacy of two options in type 2 diabetes mellitus patients whose blood glucose had not been well controlled with mitiglinide (30 mg/day) alone. "
06/05/2011 - "Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus."
05/01/2009 - "In conclusion, mitiglinide 10 - 20 mg three times daily provided similar blood glucose control to nateglinide 120 mg three times daily in type 2 DM patients, including the elderly and patients with mild diabetes mellitus."
02/01/2001 - "Our aim was to establish a diabetes mellitus model in dogs, and then during an oral glucose tolerance test to compare the hypoglycemic effect and insulinotropic action of KAD-1229, a new hypoglycemic agent, with that of gliclazide, a conventional sulfonylurea. "
08/01/1996 - "We also tested the efficacy of KAD-1229 in more severe STZ-induced NIDDM (sNIDDM) rats to elucidate the effects of the drug on the long-term glycemic controls and diabetic complications. "
08/01/1996 - "We conclude that the rapid- and short-acting insulinotropic agent KAD-1229 is able to improve the deterioration in the glycemic controls and inhibit the development of diabetic complications in STZ-induced NIDDM rats."
08/01/1996 - "A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats."
|3.||glargine (insulin glargine)
|4.||insulin aspart (NovoLog)
|5.||Blood Glucose (Blood Sugar)